

PANCREAS  
DISEASE ORIENTED GROUP  
AGENDA  
**OPEN SESSION**

VENUE: ROSSETTI ROOM, CHELSEA HOTEL, TORONTO

DATE SATURDAY, APRIL 30<sup>th</sup>, 2016

TIME: 11:00 - 12:00

**CHAIRS: DR. ALICE WEI & DR. DANIEL RENOUF**

- 
- 11:00 WELCOME AND INTRODUCTION **DR. A. WEI / DR. D. RENOUF**
- 11:05 ACTIVE TRIALS FOR UPDATE/DISCUSSION
- PA.6 (ACCORD 24):** RANDOMIZED MULTICENTER PHASE III COMPARISON OF ADJUVANT CHEMOTHERAPY WITH GEMCITABINE VERSUS A COMBINATION OF 5-FLUOROURACIL, LEUCOVORIN, IRINOTECAN AND OXALIPLATIN (MFOLFIRINOX) IN PATIENTS WITH RESECTED PANCREATIC ADENOCARCINOMA **DR. A. WEI / DR. J. BIAGI**
- 11:15 APPROVED TRIALS IN DEVELOPMENT
- PA.7:** A RANDOMIZED PHASE II TRIAL OF GEMCITABINE AND NAB-PACLITAXEL VS. GEMCITABINE, NAB-PACLITAXEL AND DURVALUMAB OR GEMCITABINE, NAB-PACLITAXEL, DURVALUMAB AND TREMELIMUMAB AS 1ST LINE THERAPY IN METASTATIC PANCREATIC ADENOCARCINOMA **DR. D. RENOUF**
- CONCEPTS IN DEVELOPMENT
- 11:35 **ALLIANCE 021101:** NEOADJUVANT FOLFIRINOX AND CHEMORADIATION FOLLOWED BY DEFINITIVE SURGERY AND POSTOPERATIVE GEMCITABINE FOR PATIENTS WITH BORDERLINE RESECTABLE PANCREATIC ADENOCARCINOMA: AN INTERGROUP SINGLE\_ARM PILOT STUDY **DR. A. WEI / DR. S. GALLINGER**
- 11:40 **SWOG S1505:** FOLFIRINOX *VERSUS* GEMCITABINE/NAB-PACLITAXEL AS NEOADJUVANT THERAPY FOR RESECTABLE PANCREATIC ADENOCARCINOMA: A RANDOMIZED PHASE II STUDY **DR. D. RENOUF**
- 11:45 PHASE II TRIAL OF FOLFIRINOX *VERSUS* GEMCITABINE/NAB-PACLITAXEL IN PATIENTS WITH NEWLY DIAGNOSED METASTATIC BRCA WT PANCREAS CANCER **DR. D. RENOUF**
- 11:50 COMPASS/PANGEN SEQUENCING UPDATE **DR. D. RENOUF**
- 11:55 INTERGROUP TASK FORCE UPDATE **D. RENOUF / DR. A. WEI**
- 12:00 CLOSING REMARKS